2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Pathology, Profiling, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Antibody Therapy, Biological Processes, Apoptosis, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Bleeding and Clotting, Bleeding Disorders, Thromboembolism, Thrombotic Disorders, VWD, Immunology, Autoimmune Disorders, Research, Fundamental Science, Translational Research, Study Population, Human, Animal Model
PAPER

1311 Clonal heterogeneity of anti-PF4/heparin antibodies in patients with heparin-induced thrombocytopenia

Adam J. Kanack, PhD, Emily Armstrong, BS2, Mindy Kohlhagen, BS3, Jon Coker, PhD4, David L Murray, MD, PhD5, Anand Pabmanabhan, MBBS, PhD6
1 Mayo Clinic, Phoenix, Arizona, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States

Background: Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating antibodies targeting complexes of platelet factor 4 (PF4) and heparin. HIT antibody responses are generally transient and have historically been considered polyclonal or polyspecific. In contrast, a recent study reported that affinity-purified, platelet-activating anti-PF4/heparin antibodies were monoclonal in nine patients; in most cases (6/9), the anti-PF4/heparin antibody corresponded to a serum immunofixation-detectable M-protein. These findings raise two related questions: whether HIT-associated PF4/heparin-reactive antibody responses are monoclonal, oligoclonal, or polyclonal, and whether any clonally restricted response corresponds to a detectable whole-serum monoclonal protein that might prompt consideration of monoclonal gammopathy of undetermined significance (MGUS) or monoclonal gammopathy of thrombotic significance (MGTS). We characterized the clonality of patient IgG preparations immunoenriched for PF4/heparin-reactive antibodies and compared immunoenriched clonotypes with the whole-serum immunoglobulin repertoire.

Methods: Remnant serum samples from 15 adults with intermediate- or high-probability 4Ts scores and laboratory-confirmed HIT were analyzed. Whole serum underwent Mass-Fix (MALDI-TOF MS), PF4/heparin ELISA, serotonin release assay, and PF4-dependent P-selectin expression assay (PEA). PF4/heparin-reactive antibodies were affinity-enriched, assessed by ELISA and PEA, and characterized by liquid chromatography-electrospray ionization-quadrupole time-of-flight mass spectrometry (LC-ESI-QTOF). Clonal classification combined light-chain mass distributions with heavy-chain spectra before and after PNGase F treatment to directly compare immunoenriched clonotypes with the whole-serum immunoglobulin repertoire.

Results: All sera tested positive by PF4/heparin ELISA and serotonin release assay, and 14 of 15 were positive by serum PEA. All immunoenriched IgG preparations retained PF4/heparin reactivity, with 14 of 15 activating platelets by PEA. Among patient IgG preparations immunoenriched for PF4/heparin-reactive antibodies, 8 of 15 (53%) were clonally restricted, while 7 of 15 (47%) showed evidence of multiple antibody clones. None of the 8 restricted immunoenriched clonotypes corresponded to a Mass-Fix-detectable whole-serum monoclonal protein. Low-level IgG serum monoclonal proteins were detected by Mass-Fix in 2 of 15 patients (13%; 40.5 and 31.4 mg/dL), but in both cases, the serum monoclonal-protein mass differed from the immunoenriched anti-PF4/heparin antibody mass. Among the seven immunoenriched preparations showing multiple light-chain species, all five with sufficient material for heavy-chain analysis retained multiple deglycosylated heavy-chain masses; a clonally restricted preparation yielded a single dominant heavy-chain mass, supporting the classification.

Conclusions: PF4/heparin-immunoenriched patient IgG preparations showed heterogeneous clonal patterns: approximately half were clonally restricted, whereas half showed evidence of multiple antibody clones. In this cohort, none of the restricted immunoenriched clonotypes corresponded to a Mass-Fix-detectable whole-serum monoclonal protein. These findings refine prior reports by showing that PF4/heparin-immunoenriched patient IgG preparations were not uniformly monoclonal in this cohort and that clonal restriction detected after PF4/heparin immunoenrichment does not by itself establish a circulating monoclonal protein or MGUS/MGTS. Given the divergent therapeutic implications of HIT and MGTS, clonal restriction detected after PF4/heparin immunoenrichment alone should not establish MGTS or justify clone-directed therapy.

Adam J. Kanack, PhD: Mayo Clinic - Patents & Royalties